Alder S, Megyessi D, Sundström K, et al. - Researchers investigated 991 women previously treated for cervical intraepithelial neoplasia 2/3 for the long-term risk of residual/recurrent high-grade cervical intraepithelial neoplasia. Further, they assessed how this risk varies with respect to margin status (considering also location), as well as comorbidity (conditions assumed to interact with high-risk human papillomavirus acquisition and/or cervical intraepithelial neoplasia progression), posttreatment presence of high-risk human papillomavirus, and other factors. During a median of 10 years and maximum of 16 years of follow-up, residual/recurrent high-grade cervical intraepithelial neoplasia or worse was diagnosed in 111 patients. They observed an increased risk for residual/recurrent high-grade cervical intraepithelial neoplasia or worse among patients with incompletely excised cervical intraepithelial neoplasia 2/3. The accuracy for predicting treatment failure may improve on considering margin status combined with high-risk human papillomavirus results and comorbidity.